Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
May 4, 2023
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, everyone, and thank you for being with us on today's call. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's recently been happening. Fady Malik, who serves as EVP of R&D, will share updates concerning aficamten along with the other drug candidates that make up our early-stage pipeline. We'll then hear from Stuart Kupfer, SVP and Chief Medical Officer, who has further updates on the aficamten development program. Andrew Callos, EVP and Chief Commercial Officer, will talk more about commercial preparation work for aficamten as well as the market opportunity. A financial review of the quarter just ended will come from Robert Wong, VP and Chief Accounting Officer; and Ching Jaw, SVP and Chief Financial Officer, will cover our financial outlook together with corporate development strategies. To wrap up, Robert Blum will offer closing remarks and go over the key milestones we expect in 2023. Be aware that some parts of what we discuss next, including answers to your questions, include statements tied to future events and performance instead of historical facts, which means they are forward-looking statements. The results we actually achieve could differ materially from what those forward-looking statements project. You can find additional information about the factors that might cause our actual results to differ materially from those in these forward-looking statements in our SEC filings, including our current report on our first quarter 2023 financial results, filed on Form 8-K and furnished to the SEC today; we take on no obligation to update any forward-looking statements after this call. With that, I'll hand the call over to Robert.
Robert Blum
executiveThank you, Diane, and I appreciate everyone being with us on today's call. We kicked off the first quarter with a clinical-stage program aimed at potentially treating ALS, but by the time the quarter closed, we recognized we could no longer make that commitment; putting the science and our shareholders first means accepting that situation and refocusing on what offers the most hope for patients. With that in mind, let me stress how confident we are in our specialty cardiovascular pipeline of novel cardiac muscle-directed drug candidates, and how firmly we prioritize it. Even with the setback on ALS, the first quarter of 2023 brought meaningful advances throughout our cardiovascular pipeline, especially for aficamten and its extensive development program. Fady and Stuart will go into detail, but screening in SEQUOIA-HCM, our pivotal Phase III clinical trial in patients with obstructive HCM, should wrap up tomorrow, which lets enrollment finish within a few weeks and results read out in the fourth quarter of this year, just as planned. We also recently shared data from Cohort 4 of REDWOOD-HCM and 48-week data from FOREST-HCM, and together they offer strong support for our next-in-class cardiac myosin inhibitor. Lastly, we advanced efforts to broaden aficamten's development, with plans to launch MAPLE-HCM soon — the active comparator Phase III trial against metoprolol — and we kept getting ready for our planned Phase III clinical trial of aficamten in nonobstructive HCM. As you're aware, we also got a Complete Response Letter from the FDA for omecamtiv mecarbil during the quarter. We remain in discussions with FDA and intend to meet with them this quarter to go over their feedback and gain a clearer picture of what our options might be going forward. Once we have something more substantive to share, we expect to give an update. Meanwhile, we continue pushing toward possible international approvals for omecamtiv mecarbil. In Europe, we're working with EMA as it reviews the MAA and getting ready to answer Day 120 questions. And in China, the Center for Drug Evaluation of the National Medical Products Administration is reviewing the NDA submission for omecamtiv mecarbil. As I noted earlier, during the first quarter we also announced that COURAGE-ALS, the Phase III clinical trial of reldesemtiv, hit the futility criteria at the second planned interim analysis. Our commitment to the ALS community over the last decade has defined our dedication to novel muscle-directed medicines, and it's disappointing that we won't be able to advance a drug candidate for patients facing this terrible disease. Based on the interim analysis data, we've moved to end study-conducted COURAGE-ALS, and we're finishing closeout activities for this trial and the open-label extension study during this second quarter. Full results from COURAGE-ALS are slated for presentation at a medical meeting later this year. We carried out this study with scientific rigor and for the benefit of individuals living with ALS, and our hope is that it can act as a model for performing thorough, patient-focused clinical research. Obviously, we are deeply let down by what happened with COURAGE-ALS, yet it gives us a chance to capture some savings during 2023, which we think can lengthen our cash runway and let us shift resources so that our attention on aficamten grows even stronger. Before this, more than 60% of our R&D budget already went to aficamten, but given the savings we now anticipate in 2023, a still greater share of our overall spending will go toward aficamten. Ching will go into more detail shortly about what we expect to spend in 2023. So even though the first quarter delivered a few unforeseen difficulties, our dedication to the mission of advancing new treatments for patients facing diseases with high unmet need has not wavered at all. Both our late-stage and early-stage pipeline of possible cardiovascular medicines offers a clear way forward, backed by our robust balance sheet, to sustain ongoing execution for the good of every one of our stakeholders; and now, I'll hand the call to Fady.
Fady Malik
executiveThank you, Robert. During Q1, we achieved meaningful strides throughout a wide-ranging development initiative for aficamten. At ACC in March, we shared results from REDWOOD-HCM's Cohort 4, demonstrating that aficamten therapy produced notable gains in heart failure symptoms along with cardiac biomarkers among patients suffering from nonobstructive HCM. Cohort 4 functioned as a dose-finding effort that permitted 2 titration steps, aiming to escalate dosage guided by echocardiography while assessing impacts on symptoms and biomarkers. As a reminder, whereas obstructive HCM calls for titrating individuals to the minimal effective dose needed to remove the LVOT gradient, nonobstructive HCM instead requires titrating to the maximum dose according to injection fraction; within Cohort 4, by Week 6, 85% of patients reached the top dose of 15 milligrams of aficamten. Crucially, even while pushing patients to higher doses, no discontinuations occurred because of adverse events. As previously reported, 3 patients experienced LVEF declines beneath 50 at the Week 10 visit. Yet LVEF returned to normal for all 3 of those patients following the 2-week washout period. Findings from this dose-finding cohort will shape the Phase III dosing approach. Regarding safety, aficamten was well tolerated. One death occurred from sudden cardiac death that was unrelated to aficamten treatment. This patient had a prior history of sudden cardiac death before enrolling in REDWOOD-HCM. 2 days before the event, the patient's LVEF was normal, symptoms and biomarkers had improved, and aficamten's plasma concentration fell within the expected range. Both we and the investigator consider the death unrelated to aficamten, so we stay confident regarding aficamten's safety and tolerability. Extending the ACC presentation, later this month we're glad to share additional Cohort 4 data during the late-breaking clinical trial session at the European Society of Cardiology's Heart Failure 2023, held in Prague. These findings will encompass data from extra patients excluded from the ACC results because of timing, plus information tied to the Kansas City Cardiomyopathy Questionnaire and other further findings. To offer perspective on what cardiac myosin inhibition aims to achieve in nonobstructive HCM, it's worth noting that even though such patients have no significant LVOT gradient, their disease burden—measured through NYHA Class and KCCQ plus biomarkers such as NT-proBNP—is equally severe as that of patients with obstructive HCM. The degree of improvement in these disease burden markers that we saw with aficamten proved substantial, almost matching what we saw in obstructive HCM, and offers a robust signal of treatment benefit. We're happy with the initial Cohort 4 data, and we regard them as both supporting progression to Phase III and strongly encouraging regarding a possible aficamten effect within this key HCM population segment. Also, at ACC, we shared 48-week results from FOREST-HCM, our open-label extension trial, which demonstrated that aficamten treatment was tied to substantial and lasting decreases in the average resting in Valsalva LVOT gradient, along with meaningful gains in NYHA Class and meaningful gains in NT-proBNP. By week 48, 88% of patients saw an improvement of at least 1 NYHA functional class, among them numerous patients who no longer show symptoms. Among those who made it to 48 weeks, not a single one stayed in NYHA Class III, whereas 47% of patients were in Class III when they started. Easing symptoms can make a deeply positive difference in patients' lives; therefore, these findings are rather noteworthy. Aficamten treatment seemed safe and well tolerated, and there were no cases of treatment interruption or discontinuation linked to aficamten. We take encouragement from the fact that, with longer-term aficamten treatment, patients are seeing a durable treatment benefit. From these findings, we're gaining not just a sharper view of the possible upside aficamten may offer patients, but also how aficamten seems to hold potential for optimizing the experience of both patients and physicians. Over the quarter, we kept running SEQUOIA-HCM, the pivotal Phase III clinical trial of aficamten in patients who have obstructive HCM. As Robert noted, we anticipate finishing patient screening tomorrow and randomizing the final patient shortly after that. We feel enormous gratitude toward all our investigative sites worldwide for collaborating with us to reach this milestone. Not long ago, the DMC examined safety, efficacy and biomarkers for SEQUOIA-HCM and advised that the trial proceed as planned. With enrollment almost finished, we're happy with the patient population we enrolled and think we're hitting our aim of concentrating on patients who are positioned to gain from aficamten. We hit 4 key enrollment targets that leave us confident in the results we anticipate. First, the share of patients taking beta blockers as background therapy, which restrict heart rate from rising and can dull exercise performance, matched what we expected. Second, we enrolled patients whose exercise capacity was clearly impaired, shown by an average baseline peak VO2 far below normal. Third, the share of patients using a bicycle or treadmill for their exercise test matched what we expected. And lastly, enrollment in SEQUOIA-HCM happened globally, bringing in a balanced and diverse patient population across the U.S., Europe, Israel and China; we believe that how we've designed and carried out SEQUOIA-HCM and the patient population we've enrolled will help deliver a clear read on aficamten's potential efficacy and safety. Before I pass it to Stuart, I also want to briefly mention our earlier-stage pipeline. First, during the prior quarter, we finished 3 ascending dose cohorts in the Phase I study of CK-136, our cardiac troponin activator, in healthy volunteers and anticipate data in the second half of the year. Also, after our IND submission for our second cardiac myosin inhibitor, CK-586, we got FDA clearance to launch its Phase I study. Program 586 is an important new clinical initiative that broadens our pipeline. We plan to develop it as a possible therapy for heart failure with preserved ejection fraction—one more meaningful addition to our expanding specialty cardiology business. With that, I'll hand things over to Stuart, who can share more about the growing development effort for aficamten, covering MAPLE-HCM as well as the Phase III clinical trial we have planned in nonobstructive HCM.
Stuart Kupfer
executiveAppreciate that, Fady. During Q1, we moved closer to getting MAPLE-HCM underway, and we anticipate that patient enrollment will open during the current quarter. Just to reiterate, MAPLE-HCM stands as our second Phase III clinical study involving individuals who have obstructive HCM, and in it we will evaluate aficamten given as monotherapy against metoprolol. The main endpoint being measured is the shift in peak VO2, as determined through cardiopulmonary exercise testing, between baseline and Week 24. Among the secondary endpoints are changes in NYHA Class, KCCQ, NT-proBNP, along with indicators of structural remodeling. What we aim to accomplish with this study is to assess whether aficamten might prove superior to the current standard of care, which is beta blocker therapy. For most HCM patients, beta blockers serve as the first-line treatment, since few other options have existed historically. Although beta blockers are capable of lowering gradients and producing modest symptom relief, a significant share of patients fail to get the symptom reduction they need from beta blockers, and these drugs come with numerous unwanted side effects. On top of that, beta blockers fail to boost exercise capacity. What's more, if given alongside a cardiac myosin inhibitor, they could weaken that drug's positive effects. Should aficamten demonstrate superiority over metoprolol, the way HCM is treated could become simpler, since aficamten might then be used as first-line monotherapy. We take encouragement from the data shared earlier out of FOREST-HCM, which showed patients on aficamten successfully coming off background therapy, and the sites running our clinical studies are eager to take part in this trial. We're excited to get enrollment going in MAPLE-HCM before long. Also, as Fady noted, the favorable results from Cohort 4 of REDWOOD-HCM that were presented at ACC gave us confidence for our intention to broaden the aficamten development program further by launching a Phase III clinical trial focused on nonobstructive HCM; we've had productive conversations with the FDA lately to get set for that trial. Our planning and preparations are being wrapped up, and we anticipate this third Phase III trial for aficamten kicking off during the back half of this year. We're eager to provide additional details about the design of the planned trial at some point later this year. Having said all that, I'll hand things over to Andrew.
Andrew Callos
executiveThank you, Stuart. During the first quarter, we kept up our work and planning related to a possible approval and commercial launch of aficamten, which included market research aimed at broadening our knowledge and sharpening how we describe the market and its potential. The estimated prevalence of HCM across the U.S. sits at about 700,000 to 1 million, yet when we look at patients who have actually been diagnosed — counting both obstructive and nonobstructive HCM — our estimate comes to around 290,000. That leaves a considerable undiagnosed group, as many as 700,000 patients. In our view, those not yet diagnosed make up a highly meaningful opportunity for growth of the category. Market research has taught us that the great majority of diagnosed patients right now receive beta blockers, calcium channel blockers, or a combination of the two. We also believe that roughly 2/3 of that group has symptoms and could qualify for a cardiac myosin activator such as aficamten, assuming it gains approval. Beyond that, we anticipate that the diagnosed prevalence of HCM will rise over time, growing at a mid-single-digit rate, fueled by evidence generation, treatment options that reach the market, mounting interest from patients and physicians, wider use of CMIs beyond centers of excellence, and greater overall recognition of CMIs in treating HCM. Also during the quarter, we carried on deeper conversations with payers who showed interest in HCM, in CMIs broadly, and in aficamten in particular. Because approved therapies were unavailable until recently, certain payers have only limited familiarity with HCM, yet their interest in the disease is real, particularly for patients who have oHCM or who are highly symptomatic; we regard this as a chance to educate them and raise their understanding of HCM as time goes on. Our aficamten development program was built to deliver abundant evidence showing how aficamten, if approved, could improve the experience for both patients and physicians via rapid and durable symptom relief, easy dose titration, few drug-to-drug interactions, and no need for dose interruption. With MAPLE-HCM, we are additionally trying to demonstrate that aficamten beats the standard-of-care beta blocker, which could further improve the patient experience by eliminating beta blockers entirely and allowing straightforward monotherapy. Lastly, as we described earlier in the year, most of the commercial team has been reassigned to back aficamten launch readiness efforts in case it is commercialized, and we intend to keep evaluating our resourcing to reflect the move in emphasis from omecamtiv mecarbil readiness toward aficamten readiness; we feel lucky to have a skilled and committed team whose deep expertise in cardiovascular disease markets is driving us ahead as we aim to become a global specialty cardiology company, with aficamten at the lead. With that, I'll hand things over to Robert Wong.
Robert Wong
executiveThanks, Andrew. As we closed out the first quarter, our cash and investments stood at roughly $704 million. During Q1 2023, the bulk of our revenue came from a milestone payment tied to Ji Xing that we recognized, related to the anticipated Phase III trial of aficamten in nHCM patients expected to take place later this year, along with revenue earned from Astellas during the quarter. R&D expenses for the first quarter of 2023 rose to $79.4 million, compared with $45.9 million in the first quarter of 2022, largely driven by greater spending on clinical development work for our cardiac myosin inhibitor programs and COURAGE-ALS. G&A expenses in the first quarter of 2023 reached $49.7 million, an increase from $33.1 million in Q1 2022, mainly attributable to higher personnel-related costs, including stock-based compensation, plus expenses for pre-commercial launch readiness. At this point, Ching will walk through our financial outlook and corporate development strategy.
Ching Jaw
executiveAppreciate it, Robert. We closed out the quarter with roughly $704 million in cash on the balance sheet, and that gives us 2 years of cash runway. Let me be clear — we are not making any changes to our 2023 guidance as of today. That said, we do anticipate cutting our total spending across 2023 by over 10%, mainly by scaling back on planned outsourced services along with headcount growth, and that adds up to more than $50 million in expected savings compared with what we had previously forecasted for 2023 spending. Through these steps, we can stretch our current cash runway both this year and into 2024 — a period when we had earlier expected to take on costs tied to manufacturing commercial supply, commercial readiness preparations, and medical education activities for reldesemtiv; we plan to share fresh financial guidance alongside our Q2 earnings call. To build up our balance sheet further this year, I want to remind everyone that we also anticipate collecting a $50 million nonrefundable milestone payment from Royalty Pharma once the pivotal Phase III clinical trial of aficamten in patients with nonobstructive HCM gets underway, which should happen in the second half of the year. And last, when it comes to corporate development, in order to bolster our balance sheet and our path forward even more, we are still looking this year for a possible partner in Europe for omecamtiv mecarbil, and in Japan for omecamtiv mecarbil as well as aficamten. Given recent events, we also think we might need to widen the scope on potential European partnering of aficamten as part of our larger cardiovascular portfolio. With that said, we keep preparing for U.S. commercialization on our own. And as we move our corporate development forward over the rest of this year, we will keep making calls that serve the best interests of patients and our shareholders. With that, I'll hand the call back to Robert Blum.
Robert Blum
executiveI appreciate that, Ching. As we entered 2023, our organization doesn't resemble what we thought it would be at this point. Even so, we have faith in our current position and what lies ahead. Across our 25-year history, we've gotten past obstacles previously, and we think that, with a strong R&D pipeline grounded in muscle biology serving as our foundation, we now have a chance to create the top specialty cardiology business in the industry. Looking forward, we feel optimistic and hold firm belief in aficamten, along with our other drug candidates featuring novel mechanisms that are moving through our cardiovascular pipeline. In addition, during the prior quarter, we took pride in publishing our first corporate responsibility report. That report demonstrates our dedication to, and ongoing incorporation of, corporate responsibility across our entire organization, plus our decision-making, and our sustained pledge to deliver openness and accountability regarding corporate responsibility matters. We plan to publish a yearly refresh of that report covering our progress and objectives, building upon the foundation, while we keep concentrating on ways to serve patients better, along with the communities surrounding us and the environment. As Ching noted, the cash we hold puts us in an advantageous spot, and we handle it with care. We exercise prudence in overseeing our expenditures, our expansion and how we distribute resources. We possess a promising development program featuring our cardiac myosin inhibitors, aficamten and CK-586; furthermore, we're outfitted with an early-stage and research pipeline that contributes additional strength to our collection of muscle-directed therapies. Our aim is to create value for the company via our science — that hasn't shifted — and we'll keep balancing what patients need with what shareholders need as we move ahead; next, I'll summarize our approaching milestones. Regarding omecamtiv mecarbil, we anticipate continuing to seek possible international approvals for omecamtiv mecarbil, such as in Europe and in Japan — pardon me, in China. Regarding aficamten, we anticipate presenting further data from Cohort 4 of REDWOOD-HCM at Heart Failure 2023 on May 20 in Prague, and we anticipate finishing patient enrollment for SEQUOIA-HCM in Q2 2023, with results anticipated in Q4 2023; we anticipate launching MAPLE-HCM, the second Phase III clinical trial of aficamten as monotherapy in patients with obstructive HCM, in Q2 2023. And we anticipate launching a Phase III clinical trial of aficamten in nonobstructive HCM during the second half of 2023. Additionally, we anticipate pushing forward our U.S. go-to-market strategy throughout 2023. Regarding CK-136, we anticipate single ascending dose data from the Phase I study during the second half of 2023. Regarding CK-586, we anticipate moving that compound into a first-in-human Phase I study this quarter, Q2 2023. And last, regarding reldesemtiv, we anticipate wrapping up clinical trial conduct and finishing most closeout activities for COURAGE-ALS in Q2 2023, and we anticipate sharing results during the second half of the year. Operator, at this point, please go ahead and open the line for questions.
Srikripa Devarakonda
analystRegarding aficamten, it seems like you're set to finish enrollment during the second quarter. I was just curious about how much confidence you have in the timelines for the fourth quarter. Might there be any possibility that it slips into early 2024? And then, given the Camzyos launch and whatever feedback you're getting from the field, has that altered your view on what's needed to get ready for aficamten's commercialization?
Robert Blum
executiveSure; so really 2 questions there. The first concerns enrollment. And as Fady mentioned, we do anticipate wrapping up enrollment, with randomization and enrollment both finishing in May. Consequently, we feel confident about results arriving in this year's fourth quarter. As for a possible commercial launch of aficamten, we're closely tracking how cardiac myosin inhibitors as a class are being adopted, and we're pleased with what we're seeing. In our view, the market is developing just as we anticipated, and we don't expect that to alter our thinking on commercial uptake. Perhaps I'll hand it to Andrew to see whether he'd like to add anything.
Andrew Callos
executiveYeah, Robert, I'd have to agree — BMS just put out results for their first quarter, and I'd say they demonstrated solid momentum. On top of that, from physicians we keep hearing really encouraging feedback about the whole category. So none of that shifts our view whatsoever. Honestly, if anything, we've grown even more confident about it than we might have been previously.
Salim Syed
analystThen I’ve got a single question regarding how SEQUOIA is enrolling. I simply want to be certain I’m getting this right. Fady, I’d appreciate hearing you confirm it, or at least give us some detail on the most recent occasion you reviewed the pooled, blinded standard deviation for peak VO2 in SEQUOIA. Also, could you verify that we truly are below 3.5 for that standard deviation, and that enrollment for the trial cannot go up now?
Fady Malik
executiveMy response is that there’s no danger of enrollment rising at this stage. Like I mentioned, patient enrollment wraps up tomorrow, and randomization will conclude soon after. As for the standard deviation, I can’t say precisely when I last viewed it—likely sometime during the past 7 days—but it definitely falls inside what we would expect.
Tessa Romero
analystWe have one question about nonobstructive HCM. We're eager for the complete presentation later this month covering Cohort 4. From what we remember, KCCQ is among the main endpoints you're tracking for health status. Could you give us a quick, brief orientation on how big a change you're expecting after 12 weeks of treatment on the KCCQ? Also, is there a level of change that would be viewed as clinically meaningful? And what should we anticipate regarding the approximate baseline score?
Robert Blum
executiveWell, clearly, since this is an open-label study, you understand that we've already looked at these data. So although we don't wish to get ahead of the data before the late-breaker presentation later this month, I'll have Fady do his best to address your question while not leaning too far forward.
Fady Malik
executiveI'd rather not provide specific numeric guidance, since I'm aware of what those figures actually are; however, I ought to mention that the baseline information points to a population with severe symptoms when you look at the starting KCCQ score. Broadly speaking, a rise of at least 5 points is regarded as clinically meaningful. So that's — that's the way I'd frame it for context once you're looking at the data later this month.
Tessa Romero
analystAnd is there anything else in the way of analyses we ought to be watching for, apart from KCCQ, that hasn't come out yet?
Fady Malik
executiveWe're going to present findings tied to how angina gets evaluated, and that's a measure that hasn't truly been studied in a study of this type before. So I'd say we'll be offering some initial results when it comes to handling a score in nHCM. We'll also be examining certain echo parameters, and you're going to get a bigger — a larger portion of the KCCQ information than merely the delta. So you're going to get a sense of the responders whose responses are on the smaller side or on the larger side < >.
Charles Duncan
analystRobert, and to the whole team, congratulations on getting close to complete enrollment for SEQUOIA. My guess is afi will draw plenty of questions. Therefore, I'll pose one about reldesemtiv and the FSTA program. Could that possibly be something you'd out-license? And outside the U.S., what do you intend to do with it?
Robert Blum
executiveAbsolutely. At this moment, given that study closeout work is still underway, there's simply no way for us to be certain what the final data will ultimately look like. Still, judging from the interim analysis, the data we've observed is sufficient to indicate that carrying on with that trial in ALS would not be appropriate. In other indications during Phase II, we did observe signs that reldesemtiv was active. However, given this Phase III outcome, no current plans exist for reldesemtiv on our end, though we will reevaluate once the final study data come in; that applies to both the U.S. and outside the U.S. We have additional efforts tied to FSTA skeletal muscle, and we're evaluating how those might support enhancing our pipeline's growth moving forward; and clearly, we also have further research programs reading on skeletal muscle and neuromuscular indications. Likewise, we'll be looking at all of them collectively given this recent development; so my response right now likely won't fully satisfy you, but this matter sits at the top of our minds.
Charles Duncan
analystSo let me just ask this — is it fair to assume your sights are set squarely on cardio, on earning a reputation as a top-tier cardio innovator, rather than spreading the platform across a wider set of uses?
Robert Blum
executiveI wouldn't draw that conclusion in as broad a way as you put it. That said, our clinical pipeline is aimed at specialty cardiology, and that is where the bulk of our investment spending will go. We do still run research programs aimed at other muscle types and other indications, though those generally aren't things our shareholders get visibility into, since they're at an earlier stage, and so we continue to hold them confidential. As for what shareholders mainly care about, yes, I believe you can draw the conclusion that we're focused on specialty cardiovascular medicines, and we now have 4 such drug candidates in our pipeline.
Edwin Delfin
analystThis is Edwin calling in for Carter. We have just one, regarding aficamten. How would you frame expectations for the speed at which Cytokinetics intends to turn around an NDA following the SEQUOIA data? Has that work already begun prior to the data? Then a follow-up housekeeping item. When enrollment in SEQUOIA finishes, should we anticipate a press release announcing that?
Robert Blum
executiveOn your first question, yes, that work has already begun, in which we're examining time lines, ways we might pull them in, what we can do prior to the SEQUOIA results, and how we can proceed as rapidly as possible to submit not only in the U.S. but internationally as well for a possible approval of aficamten. So that is very much a priority. And in recent weeks already, we've held many such meetings on exactly that matter. Your second question concerned whether we will be announcing completion of enrollment, and the answer is no; as for SEQUOIA, what we've said on this call is what we intend to have stand as our communication, which is we expect screening to finish tomorrow and we're going to be completing enrollment and randomization here in this month of May.
Yasmeen Rahimi
analystTeam, at the start of this week, we got a look at results from the EXPLORER trial run in China. When we put those numbers side by side with the EXPLORER study, the response to treatment looks like it was bigger; and perhaps, Fady, you might weigh in on whether something differs within the Asian population? Or could it simply be baseline demographics driving those differences? And then, even more significantly, I suppose that brings up the follow-on question of how much of the SEQUOIA population will come from China? Might that likewise be affected and perhaps push the results even higher? I'd welcome whatever insight you can offer on that front.
Robert Blum
executiveSure. Nice questions and a nice catch. Of course, we saw that communication about the China data. And I'll have Fady weigh in, and my guess is he may also hand some of that over to Stuart as well; so with the 2 of them, ideally, we'll address what you asked well enough.
Fady Malik
executiveTo start, Yasmeen, one thing worth pointing out is that peak VO2 wasn’t part of what the EXPLORER China trial measured. Because that trial didn’t include what is essentially the main functional endpoint, I don’t believe you can genuinely talk about broader outcomes in that sense. They did have meaningful gradient shifts, along with KCCQ and NYHA Class gains that were fairly large. Still, I’d be careful about drawing comparisons of response size across trials that enrolled at separate times, across different geographies, and with different populations. Stuart, would you like to — anything you’d add to…
Stuart Kupfer
executiveThat makes sense to me; speaking broadly, it's never easy to draw comparisons between different studies, yet the findings do appear promising and keep adding to the body of evidence backing cardiac myosin inhibitors around the globe. As you're aware, regarding SEQUOIA, we're working alongside our partners at Ji Xing, and we're bringing patients into the trial in China, and individuals from China have unquestionably played a part in filling up SEQUOIA's enrollment; so once the final results come in, we'll be looking at a highly varied patient population to consider and to underpin our regulatory approach across the world.
Robert Blum
executiveWe won't be giving out the exact figure — that is, what share of the patients came from China — beyond saying we think it ought to be enough for registration there.
Akash Tewari
analystIn your opinion, what makes partnering aficamten across Europe the better move for shareholders compared with selling the whole company outright, particularly prior to SEQUOIA reading out? Hearing that on today's call caught me somewhat off guard. And what factors could actually tip that choice in either direction? Also, do you have any views about putting out baseline characteristics for the SEQUOIA population at midyear, before the Q4 readout?
Robert Blum
executiveI'll take the first one and have Fady handle the second. What Ching meant by that remark wasn't that we've locked ourselves into partnering aficamten beyond the United States — rather, we believe shareholders benefit when we evaluate whatever might be achievable. As for your question on whether to pursue that route instead of selling the company, clearly we can't get into that on a call such as this, since those matters shouldn't be discussed given what our corporate development strategy could be. Our approach to corporate development is very much about maximizing shareholder value for the things within our direct control. This is among those things we can control, in terms of the best way to let us access capital and do what's best for science, patients and shareholders. So we feel it's our obligation to evaluate what might be achievable; and up to this point, there have been many inquiries regarding aficamten, and we've stayed fairly closed-minded about entertaining them; but given recent developments at Cytokinetics, we believe it serves our interest and shareholders' to at least widen the aperture toward those possibilities, and that's what we plan to do. Your next question concerned baseline characteristics in SEQUOIA, and perhaps I'll have Fady comment on what our plans might be there.
Fady Malik
executiveAppreciate that, Akash. That’s a question I’ve gotten previously. We are considering if it might be possible for us to bring together the final baseline data and locate a place where they can be presented. They probably won’t arrive much ahead of the final data from SEQUOIA — or, more accurately, the top line data from SEQUOIA. But once we have a sense of what we intend to do on that front, we’ll certainly update everyone.
Jeff Hung
analystI realize this hinges on what SEQUOIA ends up showing, but how are you viewing the possible scenarios that could play out for REMS on the aficamten label? For instance, what do you figure you would have to demonstrate in order for REMS to be lighter than the ones attached to Camzyos — or to avoid REMS altogether?
Robert Blum
executiveWell, clearly that's a tough one to respond to before we've got SEQUOIA results and while we're still generating solid open-label extension findings. Even so, our hope is that data from FOREST-HCM, along with SEQUOIA, would let us build an argument to FDA supporting either a reduced REMS or none at all. On that point, speculating is genuinely hard before the actual data arrive; but since you raised it, perhaps I'll check whether Fady or Stuart want to chime in about what they'll be watching for, which could in the end shape our regulatory approach on that front.
Fady Malik
executiveOkay, so I believe we are definitely going to examine the way in which dosing was carried out, how well it was tolerated, and adverse events tied to the requirement for keeping an eye on patients. As we noted, in FOREST-HCM, where earlier I went over the 48-week data, there were no drug discontinuations because of low ejection fraction, nor any treatment interruptions. And our hope is that such events are limited enough that monitoring for them can be suitably calibrated, so to speak, meaning perhaps there is monitoring through the titration phase and then at some point afterward, twice a year or something along those lines. But I think this is going to hinge on the data, and right now it is simply hard to speculate.
Jason Zemansky
analystCongratulations on the impressive strides. Perhaps turning to the earlier-stage pipeline; with 586 now heading into the clinic, could you give us some insight into your development approach in HFpEF? Do you continue to view this as a chance for aficamten too? And on the flip side, perhaps, where does HCM fit into the plans for 586?
Robert Blum
executiveGreat. Those are very good questions. And I'll have Fady address them. What we're pursuing in HFpEF has turned into a core element of our development strategy. 586 is a compound whose origins lie in the same science and biology from which aficamten emerged, yet it belongs to a quite distinct chemical class and works through a different mechanism. So because of that, we believe it might be more appropriate for our HFpEF development efforts. And Fady can discuss the therapeutic hypothesis and how we expect that to move ahead.
Fady Malik
executiveThus, CK-586, in the way we've created it, shares many characteristics with aficamten, including a shallow exposure-response relationship. We believe it's fairly free of drug-drug interactions, and we expect dosing to be predictable, with PKs suitable for a compound requiring titration and reversibility. What we've chosen to do strategically is truly split the development of HCM from HFpEF by taking aficamten and advancing it specifically in HCM. Clearly, the patient population there differs greatly from the HFpEF population. On the other hand, 586 is something meant to be developed specifically in HFpEF, so we don't, in a sense, muddy which drug to use where and so on. Therefore, we're eager to launch Phase I for 586 soon, and after that, move into what would be an initial effort to examine and investigate this in HFpEF; we'll share further specifics as the program advances.
Robert Blum
executiveSure, what we've accomplished using aficamten in nHCM gives us insight into what 586 might be able to do in HFpEF. We observe a connection in that regard, and it backs up this mechanism while justifying further study.
Jason Butler
analystCongratulations on the advancement. Just one regarding nonobstructive HCM. Since there clearly aren't gradients in this case, could you discuss how you believe biomarker monitoring might fit into clinical practice here, as opposed to simply managing symptoms? Is there anything that — how do you expect pricing might develop here?
Robert Blum
executiveThat's a good question. I'll hand it over to Fady and Stuart for that.
Fady Malik
executiveOkay, so regarding the way this medication might be used for HCM in actual practice, my view is that what steers the doctor is going to be symptoms and gains in how the patient functions, more than any biomarker. That said, they will definitely be interested in seeing NT-proBNP decline, since that signals a biological response — but for a good while we simply won't know much about the magnitude of the drop required or what it ultimately means for the patient over time. So in many respects, patient-reported feeling and whether symptoms still have room to improve as the dose goes up will drive the decisions. Stuart, anything to add — any other perspective on that?
Stuart Kupfer
executiveYeah, I'd say you've got that exactly right. What it does is give us additional data on how symptoms and function get better over time, and how those changes line up with the pharmacodynamic markers that we anticipate will show improvement.
Fady Malik
executiveHaving an objective biomarker while you’re administering a therapy seems like a good thing, since evaluating symptoms can occasionally be difficult. That makes the biomarker useful, though it likely won’t determine adoption.
Rohit Bhasin
analystI'm filling in for Serge here. Could you discuss what your regulatory approach looks like for aficamten across Europe? Would the studies you're currently conducting satisfy what's needed? Or should we anticipate further trials?
Robert Blum
executiveThose are fair questions. We genuinely think that how SEQUOIA is being carried out, on a worldwide basis, ought to meet the demands in Europe as well as everywhere else around the globe. So this isn't simply shaped by what we're doing in the U.S. — it's a worldwide plan; and the same applies to how we view MAPLE and how we're handling nHCM. Every one of these is meant to be a worldwide study that ought to serve our objectives on a global scale.
Omari Baruti
analystOmari Baruti here, filling in for Madhu. A few things we'd like to ask. First off, from the MAPLE-HCM trial, what results do you believe cardiologists must observe before they'd put afi ahead of metoprolol within the oHCM gene paradigm? Then, next, when it comes to aficamten, are there factors to consider around conducting a Phase III study comparable to the Camzyos VALOR-HCM trial?
Robert Blum
executiveSo that's a question with 2 parts. First, regarding, I suppose, impacts that might postpone when septal reduction therapy becomes necessary. That covered part B of what you asked. And part A was, what again?
Omari Baruti
analystTurning to Part A, what would cardiologists have to observe from the MAPLE-HCM trial before they would place aficamten ahead of metoprolol?
Robert Blum
executiveSo on both A and B, I'll invite Fady to share his thoughts.
Fady Malik
executiveWhen it comes to MAPLE, what I'd say is this: if you have compelling evidence that aficamten delivers meaningful gains in exercise performance, KCCQ, and NYHA Class compared with beta blockers, that would absolutely give you a solid basis in the guidelines for treating it as first-line therapy. If SEQUOIA turns out the way we're hoping, it will demonstrate that adding aficamten on top of standard of care beats standard of care alone. And our hope is to show that aficamten on its own outperforms the initial standard of care, which would then justify putting it first. The thing is, physicians aren't all that enthusiastic about putting their patients on beta blockers to begin with. Those drugs can be hard to tolerate, and they come with side effects patients don't particularly like. So the data would back that up. I also think the level of interest in that trial, and how excited the physician community is about it, says a lot about how important this question is. As for whether we'd run a VALOR-like trial with aficamten, we really haven't looked at doing that so far; it's definitely something — when you consider the cardiac myosin inhibitor class, it's < > to grow the field rather than simply duplicating work that's already been completed. If we did decide to do something in surgical-eligible patients, I suspect we'd ask a somewhat different question and take it from there. But right now, there are no plans for anything VALOR-like.
Ash Verma
analystWhen it comes to Camzyos, most usage appears to be at the 2.5-mg and 5-mg strengths, while the higher doses aren't getting picked up. Does that suggest physicians, presumably, can't titrate upward — which would underscore the need for an HCM drug that's both safer and effective? And looking at it from the other side, if real-world systolic dysfunction incidence comes in lower than what the clinical study showed, could the FDA loosen the REMS if BMS asks?
Robert Blum
executiveThat two-part question is really one for BMS rather than Cytokinetics. Commenting on Camzyos dosage strengths — what they mean for patients, or what might be required to have the REMS program removed — isn't something I see as appropriate for us. We do have opinions, but sharing them publicly isn't something I think we should do.
Dane Leone
analystNice work on the progress. I'll be brief, since this has been an extremely long day. What I'd be curious to hear from your team is this: once you have the pivotal SEQUOIA results and readout, how do you plan to handle those data — which, clearly, represent a very comparable study to the predicate behind mavacamten's approval — first, in terms of how you position them in conversations with FDA, what you'd hope to secure in a labeling discussion, and what you believe matters greatly to be included on the label so the drug's clinical utility can be differentiated from mavacamten; and second, how you'd bring that forward to the clinical community to help them grasp possible benefits of guiding patients through that truly grueling 12-month process that remains such a headache with Camzyos? So, any early thoughts? Obviously, we recognize this comes before the study results, but I think we sort of know where things are heading.
Robert Blum
executiveAgain, commenting in a comparative manner about Camzyos isn't something for us to do. What I can say is that aficamten has been developed by us very much with an eye toward showing certain properties of what might be an optimal cardiac myosin inhibitor when it comes to efficacy, tolerability, safety and convenience. And I'll ask Fady to perhaps address your questions regarding what specifically we'll be looking for, and maybe Andrew would like to weigh in too on how this could ultimately factor into the marketplace; but our aim is to make sure cardiac myosin inhibition is something physicians feel comfortable reaching for when considering their patients, obstructive and nonobstructive, and not only those cardiologists who might practice in centers of excellence, but also cardiologists beyond those centers who might likewise be seeing those kinds of patients. So perhaps, Fady, would you like to begin?
Fady Malik
executiveYes, of course. I mean, clearly our hope is that SEQUOIA's findings will back a label allowing for a product that's simple for patients to take, simple for doctors to prescribe, and that gets the most out of safety and tolerability. That information is going to be provided to FDA. Those conversations are going to happen. We understand there's substantial burden on patients when it comes to dose escalation, given the requirement for echos and similar things, plus monitoring. And what we aim to do is, so to speak, follow the data and whatever they indicate is required, in order to get the greatest safety while reducing burden on patients; and I believe that serves patients' interests, and the FDA typically keeps patients' interests in mind.
Andrew Callos
executiveOn the commercial side, for Camzyos we definitely won't possess head-to-head data, and we won't be drawing comparisons. What we'll zero in on is our own dataset and how it supports a label like the one Fady outlined — ensuring we reach a wide spectrum of cardiologists, not merely centers of excellence, securing market access, assisting patients via patient services, and making certain the market landscape and ecosystem — payers, treaters, and every HCP — understand aficamten clearly, along with its possible benefits and risk, so an informed choice becomes possible. That is truly where our attention will sit.
Justin Kim
analystI’ve got perhaps a single question regarding MAPLE. Since this trial is somewhat more focused on addressing clinical and commercial matters rather than regulatory ones, are there particular patient groups the team intends to treat and observe aficamten benefiting, and might those groups be different from SEQUOIA?
Fady Malik
executiveYeah, I believe that’s exactly why we’re broadening the development program to cover nHCM. And perhaps I’ll have Stuart speak to how that fits alongside the patient population studied in SEQUOIA.
Diane Weiser
executiveWhat he's bringing up is MAPLE.
Fady Malik
executiveI understand that, though the subject he's raising is how we widen the group of patients.
Stuart Kupfer
executiveOkay, so with SEQUOIA, the patients being looked at tend to be further along in how the disease has progressed, and the majority of them are on background therapy to treat HCM. At the same time, we're thinking about aiming at a group of patients who are at a somewhat earlier point in the disease's natural course. Those specifics are going to be talked about before long, but that's more or less the overall approach. The reason is that, strategically, as we said, what interests us is finding out whether aficamten could work as first-line therapy and might even outperform the current standard of care, which is beta blocker treatment.
Justin Kim
analystAs a quick follow-up, I wanted to ask whether it makes sense to view MAPLE as a context in which you'd expect myosin inhibition to be optimally tuned, since you're preserving < >. And in that case, could you demonstrate an advantage among patients whose disease is milder?
Fady Malik
executiveThe real question, I think, is whether beta blockers, when a cardiac myosin inhibitor is used, are aiding or impeding the greatest possible patient benefit. MAPLE is therefore built to help us settle that. Regarding the population enrolled, MAPLE, as Stuart mentioned, will take in patients who may have gradients that are somewhat less severe, potentially a bit earlier in the course of their disease. If we aim to enroll people who aren't taking beta blockers, one could picture that patients with no prior therapy might be the ones brought into MAPLE. Yet when you consider HCM as one overall disease entity, you have patients such as those in SEQUOIA, who stand for those with high gradients and for one portion of the pie, patients with nHCM standing for another portion of the pie, and MAPLE patients roughly standing for something in the middle and encompassing patients like those in SEQUOIA. And in the end, the aim is to try to produce evidence across the whole pie rather than only particular slices of it, so that a genuine rationale exists for using cardiac myosin inhibitors in patients with HCM rather than in particular subsets of HCM.
Robert Blum
executiveAppreciate it, Operator, and I want to thank everyone who joined us on today's teleconference. We're grateful for the ongoing backing and attention you've shown Cytokinetics; we look forward to updating you on where things stand, particularly with aficamten, for which a great deal of news flow is expected during this year, along with a pledge regarding our investment spending that I believe strongly aligns with what our shareholders want; and given that, we'll continue to share developments with you over the rest of this year. Operator, that being the case, the call can now come to a close. Many thanks.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.